VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Bristol-Myers Squibb Company vs TC Energy Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisTC Energy Corporation
TRP · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into TC Energy Corporation's moat claims, evidence, and risks.
View TRP analysisComparison highlights
- Moat score gap: TC Energy Corporation leads (80 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); TC Energy Corporation has 4 segments (46.1% in U.S. Natural Gas Pipelines).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Weak.
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; TC Energy Corporation has 4 across 3.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
TC Energy Corporation
U.S. Natural Gas Pipelines
U.S. interstate natural gas pipeline transportation (FERC-regulated)
United States
Utilities/LDCs, power generators, LNG/export facilities, industrial users and marketers (as shippers)
Midstream pipeline operator
46.1%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Bristol-Myers Squibb Company strengths
TC Energy Corporation strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
TC Energy Corporation segments
Full profile >Canadian Natural Gas Pipelines
Quasi-Monopoly
U.S. Natural Gas Pipelines
Oligopoly
Mexico Natural Gas Pipelines
Oligopoly
Power and Energy Solutions
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.